1,442 results on '"Ribera, Josep-Maria"'
Search Results
52. Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma
53. T-ALL in CNS-3 status needs improvement
54. Iron overload refractory to phlebotomy in a patient with type 1 hereditary hemochromatosis
55. JZP458 closes the asparaginase allergy gap
56. High-porosity alkali-activated binders based on glass and aluminium recycling industry waste
57. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
58. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
59. Sustainable asphalt mixtures by partial replacement of fine aggregates with low-grade magnesium carbonate by-product
60. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
61. New drugs for follicular lymphoma
62. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group
63. Central nervous system relapse in diffuse large B cell lymphoma: Risk factors
64. Second Malignancies
65. Adherence to reporting guidelines increases the number of citations: the argument for including a methodologist in the editorial process and peer-review
66. First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
67. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment
68. Acute lymphoblastic leukemia of T progenitors: From biology to clinics
69. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
70. Sobrecarga férrica refractaria a flebotomías en un paciente con hemocromatosis hereditaria tipo 1
71. Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies
72. A Risk Score for Single-Lumen Peripherally Inserted Central Catheter (PICC)-Related Venous Thrombosis in Cancer Patients Undergoing Ambulatory Chemotherapy
73. IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
74. Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
75. Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
76. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
77. HHV8 and EBV negative primary effusion-based lymphoma: a case report of a new provisional entity and review of literature.
78. CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia
79. Genetic and phenotypic characterisation of HIV ‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
80. Poster: ALL-268 Genetic Classification of B-Cell Precursor Adult Acute Lymphoblastic Leukemia Patients Enrolled in LAL19 Trial from the Pethema Group: Response to Treatment and Survival
81. Modern Management Options for Ph+ ALL
82. P-203: Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)
83. Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old
84. Open questions in watchful waiting for follicular lymphoma
85. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients
86. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
87. Monoclonal antibodies in frontline therapy of adult acute lymphoblastic leukemia: A step ahead
88. Analysing the potential use of a low-grade magnesium carbonate by-product as a filler in hot asphalt mixtures
89. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
90. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
91. Bone marrow stromal cell regeneration profile in treated B-Cell precursor acute lymphoblastic leukemia patients: association with MRD status and patient outcome
92. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
93. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
94. Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients:Association with MRD Status and Patient Outcome
95. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols
96. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma
97. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
98. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization.
99. Detection of Kinase Domain Mutations in BCR-ABL1 Leukemia by Ultra-deep Sequencing of Genomic DNA
100. Genomics Improves Risk Stratification of Adults with T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.